U.S. FDA issued EUA for new COVID-19 over-the-counter at-home antigen test
On Apr. 14, 2023, the U.S. FDA issued an emergency use authorization for the Azure Fastep COVID-19 Antigen…
U.S. spending $5 billion to speed up development of new COVID vaccines
On Apr. 10, 2023, the U.S. Department of Health and Human Services (HHS) announced it was spending over…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | NIH | Therapeutics | Vaccine
Frequent testing reduced COVID-19 deaths in nursing facilities
On Apr. 4, 2023, National Institutes of Health (NIH) funded research was announced from the University of Rochester…
Moderna finalized agreement with Government of the Republic of Kenya to establish an mRNA manufacturing facility
On Mar. 30, 2023, Moderna and the Government of the Republic of Kenya announced they had finalized an…
Antibiotics do not cut death risk in hospitalized patients with viral respiratory illnesses
On Mar. 24. 2023, antibiotics do not reduce the risk of dying in adults hospitalized with COVID-19, the…
Biotechnology | CDC | COVID-19 | Diagnostics | Vaccine
Tuberculosis in the U.S. increased slightly during 2022 although it remained lower than prepandemic years
On Mar. 24, 2023, the U.S. Centers for Disease Control and Prevention (CDC) announced that Tuberculosis (TB) in…
Paxlovid reduced risk of long-term health problems, death from COVID-19
On Mar. 23. 2023, researchers at Washington University School of Medicine in St. Louis and the Veterans Affairs…
Quest Diagnostics announced first-of-its-kind post-COVID-19 panels available
On Mar. 21, 2023, Quest Diagnostics announced that it had introduced two innovative Post-COVID-19 panels. These laboratory tests…
Biotechnology | COVID-19 | NIH | Pharmaceutical | Vaccine
SARS-CoV-2 infection weakens immune-cell response to vaccination
On Mar. 20, 2023, NIH scientists announced that the magnitude and quality of a key immune cellﾒs response…
FDA Advisory Committee voted in support of favorable benefit-risk profile for Pfizer’s PAXLOVID
On Mar. 16, 2023, Pfizer announced that the U.S. Food and Drug Administration’s Antimicrobial Drugs Advisory Committee (AMDAC)…
FDA authorized bivalent Pfizer-BioNTech COVID-19 vaccine as booster dose for certain children 6 months through 4 years of age
On Mar. 14, 2023, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the…
‘Deaths of Despair’ contributed to 17% rise in Minnesota’s death rate during COVID-19 pandemic
On Mar. 13, 2023, Mayo Clinic published a study that showed the COVID-19 pandemic was linked to a…
Biotechnology | COVID-19 | FDA
QuidelOrtho received de novo FDA authorization for Sofia 2 SARS Antigen+ FIA
On Mar. 8, 2023, QuidelOrtho announced that it had been granted a De Novo request from the U.S….
In a first for imaging, new microscope captured details, 3D motion of molecules in liquid
On Mar. 7, 2023, researchers at Washington University School of Medicine in St. Louis and the Veterans Affairs…
Pfizer and BioNTech submitted for U.S. EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 booster in children under 5 years
On Mar. 1, 2023, BioNTech and Pfizer announced that they had submitted an application to the U.S. Food…
FDA authorized first OTC at-home test to detect both influenza and COVID-19 viruses
On Feb. 24, 2023, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for…
Moderna to make milestone payments to NIH for COVID vaccine
On Feb. 24, 2023, Moderna announced will make certain contingent development, commercial and regulatory milestone payments to the…
Vekluryﾮ (Remdesivir) reduced risk of mortality in hospitalized COVID-19 patients across all variants in real world study
On Feb. 21, 2023, Gilead Sciences announced positive data from three retrospective real-world studies which demonstrated that initiation…
Higher-Dose and longer duration of Ivermectin not effective with COVID-19
On Feb. 20, 2023, results from a randomized clinical trial of Ivermectin in a higher-hose and longer duration…
Health Canada authorized Moderna’s Omicron-targeting bivalent COVID-19 vaccine in children & Adolescents
On Feb. 17, 2023, Moderna announced that Health Canada had authorized the use of its Omicron-targeting bivalent COVID-19…
Lancet study published on natural immunity protection by COVID variant
On Feb. 16, 2023, it was reported in the Lancet that protection from past infection against re-infection from…
Moderna to provide free COVID-19 vaccines after U.S. public health emergency ends
On Feb. 15, 2023, Moderna announced it will continue to offer its COVID-19 vaccines for free, even after…
U.S. Government and Novavax extend partnership for 1.5 million additional doses of Novavax’ COVID-19 vaccine
On Feb. 13, 2023, Novavax announced a modification to its existing agreement with the U.S. Department of Health…
Biotechnology | COVID-19 | Diagnostics | FDA | Infectious Disease | Influenza | Vaccine
BD received FDA EUA for COVID-19, influenza A/B, RSV combination test
On Feb. 8, 2023, BD announced that it had received Emergency Use Authorization from the U.S. Food and…
Bivalent boosters provided better protection against severe COVID-19
On Feb. 7, 2023, an NIH funded study by University of North Carolina reported that Bivalent booster vaccines…
U.S. household spread of flu more than doubled during the 2021-2022 season compared to pre-COVID-19 pandemic levels
On Jan. 26, 2023, Centers for Disease Control and Prevention (CDC) reported that U.S. household spread of flu…
Roche launched COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant
On Jan. 25, 2023, Roche and its subsidiary TIB Molbiol announced they had developed a COVID-19 PCR test…
OHSU researchers found immune response to COVID-19 strengthens over time
On Jan. 25, 2023, researchers at Oregon Health & Science University (OHSU) reported that Immunity from COVID-19 appears…
Novavax Nuvaxovid COVID-19 vaccine approved in South Korea as an adult booster
On Jan. 18, 2023, Novavax announced that partner SK bioscience had received expanded manufacturing and marketing approval from…
Moderna announced mRNA-1345, an investigational RSV Vaccine, met primary efficacy endpoints in phase 3 trial
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…